Status:
COMPLETED
Catheter Ablation of All Inducible AT Post AF Ablation
Lead Sponsor:
AZ Sint-Jan AV
Conditions:
Atrial Tachycardia
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In the treatment of symptomatic drug resistant persistent atrial fibrillation (Ps AF), catheter ablation has a class IIA indication. During the follow-up, a significant amount of patients (\~50%) will...
Eligibility Criteria
Inclusion
- Male or Female Adults (≥18 years old)
- Patients with stable ATPAF at least two months after the first AF ablation procedure.
- Consent signed by the patient after reading the information leaflet
Exclusion
- Mental or physical inability to take part in the study
- Spontaneous AF in the EP lab
- Presence of any pulmonary vein stents
- Presence of any pre-existing pulmonary vein stenosis
- Presence of any cardiac valve prosthesis
- Clinically significant mitral valve regurgitation or stenosis
- Myocardial infarction, PCI / PTCA or coronary artery stenting within the last 3 months
- Unstable angina
- Any cardiac surgery within the last 3 months
- NYHA class III or IV congestive heart failure
- Uncontrolled hyperthyroidism
Key Trial Info
Start Date :
April 5 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03343860
Start Date
April 5 2017
End Date
May 31 2022
Last Update
August 3 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Department Clinical Trial Cardiology
Bruges, Belgium, 8000
2
Hôpital Cardiologique d Haut Leveque
Bordeaux, France, 33304
3
CHU Toulouse
Toulouse, France
4
Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz
Mainz, Germany